KRAS and non-small cell lung carcinoma: Another trial (NCT05202561) is recruiting patients with advanced KRAS-mutated NSCLC to evaluate mRNA vaccine safety, tolerability, anti-tumor efficacy, immunoreactivity, and pharmacokinetics either as monotherapy or in combination with ICIs.